Maribavir (Livtencity)

Key Messages

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses maribavir (Livtencity) 400 mg (2 tablets of 200 mg) twice daily resulting in a daily dose of 800 mg.
• Indication: Treatment of adults with post-transplant cytomegalovirus (CMV) infection or disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.